- Investors and analysts have overestimated the market size for SBC-102 by at least 3-9x.
- Most sufferers of CESD can be treated by proper diet and common statins (i.e. Lipitor) without the need for a $300,000 drug.
- Management has now sold 95% of its stock, reducing combined holdings to less than 1% of outstanding – even before their drug has completed trials.
- Similar to Raptor and Aegerion, Synageva will likely drop by at least 50% from current levels.